TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28413427
Drug: RSV F
Normalized name: Respiratory syncytial virus fusion protein.
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSV F nanoparticle vaccine (adjuvanted)
Study: 28413427
Drug: RSV F
Normalized name: Respiratory syncytial virus fusion protein.
Approvals — FDA: no, EMA: no, PMDA: no
Description: RSV F nanoparticle vaccine co-administered with TIV
Study: 28415102
Drug: Fetuin-A level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fetuin-A level ≤0.53 g/L
Study: 28415102
Drug: Fetuin-A level
Normalized name: peanut allergenic extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fetuin-A level >0.53 g/L
Study: 28416015
Drug: Augmentation therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Augmentation therapy (AT)
Study: 28416015
Drug: No augmentation
Approvals — FDA: no, EMA: no, PMDA: no
Description: No augmentation therapy (AT)
Study: 28416221
Drug: Ombitasvir 25
Normalized name: Ombitasvir
DrugBank: Ombitasvir (DB09296)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Ombitasvir 25 mg, paritaprevir 150 mg, and ritonavir 100 mg, plus dasabuvir 250 mg for 8 weeks
Study: 28416559
Drug: Nitroglycerin-based catheter
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nitroglycerin-based catheter lock solution (15 or 30 μg/ml of nitroglycerin in combination with 4% sodium citrate and 22% ethanol)
Study: 28416559
Drug: Standard care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard care (saline or heparin flush)
Study: 28417284
Drug: Voxtalisib 70
Normalized name: Voxtalisib
DrugBank: Voxtalisib (DB12400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voxtalisib 70 mg QD
Study: 28417284
Drug: Voxtalisib 50
Normalized name: Voxtalisib
DrugBank: Voxtalisib (DB12400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voxtalisib 50 mg BID
Study: 28417284
Drug: Voxtalisib 60
Normalized name: Voxtalisib
DrugBank: Voxtalisib (DB12400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voxtalisib 60 mg QD (MTD)
Study: 28417284
Drug: Voxtalisib 40
Normalized name: Voxtalisib
DrugBank: Voxtalisib (DB12400)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voxtalisib 40 mg BID (MTD)
Study: 28417284
Drug: Voxtalisib (all
Approvals — FDA: no, EMA: no, PMDA: no
Description: Voxtalisib (all doses)
Study: 28417296
Drug: DPP4 inhibitors
Normalized name: Fibrinolysis inhibitor
DrugBank: Aprotinin (DB06692)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: DPP4 inhibitors (saxagliptin)
Study: 28420281
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) during hospitalization for STEMI
Study: 28420281
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) during hospitalization for NSTEMI
Study: 28420281
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) during hospitalization for UA
Study: 28420281
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) at discharge for STEMI
Study: 28420281
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) at discharge for NSTEMI
Study: 28420281
Drug: Dual antiplatelet
Normalized name: Tums Dual Action
DrugBank: Alginic acid (DB13518)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dual antiplatelet therapy (DAPT) at discharge for UA
Study: 28420664
Drug: Intravenous iron
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous iron administration according to hospital's preoperative pathway
Study: 28421334
Drug: Pharmacological treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmacological treatment for at least 8 weeks
Study: 28422751
Drug: Dendritic cell
Normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dendritic cell vaccine (DC vaccine) injected intradermally in high doses over 2 years
Study: 28422751
Drug: Dendritic cell
Normalized name: Dendritic cells vaccine
DrugBank: Dendritic cells vaccine (DB15803)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dendritic cell vaccine (DC vaccine)
Study: 28422758
Drug: Regorafenib 80
Normalized name: Regorafenib
DrugBank: Regorafenib (DB08896)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Regorafenib 80 mg daily plus cetuximab 200 mg/m2 loading dose, followed by 150 mg/m2 every week
Study: 28423296
Drug: Eltrombopag plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag plus standard immunosuppressive therapy (cohort 1: day 14 to 6 months)
Study: 28423296
Drug: Eltrombopag plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag plus standard immunosuppressive therapy (cohort 2: day 14 to 3 months)
Study: 28423296
Drug: Eltrombopag plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag plus standard immunosuppressive therapy (cohort 3: day 1 to 6 months)
Study: 28423296
Drug: Eltrombopag plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag plus standard immunosuppressive therapy (combined cohorts)
Study: 28423296
Drug: Eltrombopag plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eltrombopag plus standard immunosuppressive therapy
Study: 28424071
Drug: Imatinib (400
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib (400 mg per day)
Study: 28424085
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy with antibiotics
Study: 28424085
Drug: Less drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less drug pressure
Study: 28424891
Drug: Selumetinib plus
Normalized name: selumetinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib plus Erlotinib (100 mg QD)
Study: 28424891
Drug: Selumetinib plus
Normalized name: selumetinib
DrugBank: Selumetinib (DB11689)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Selumetinib plus Temsirolimus (25 mg once weekly)
Study: 28426120
Drug: Olaratumab 20
Normalized name: Olaratumab
DrugBank: Olaratumab (DB06043)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Olaratumab 20 mg/kg intravenously every 14 days until disease progression, death, or intolerable toxicity.
Study: 28426811
Drug: Oral azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral azithromycin (if PCT <0.5 ng/ml)
Study: 28426811
Drug: Levofloxacin (if
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levofloxacin (if PCT ≥0.5 ng/ml)
Study: 28427434
Drug: AdCD40L gene
Normalized name: Immature cell growth-inhibiting gene 1 protein
DrugBank: Cerliponase alfa (DB13173)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: AdCD40L gene therapy
Study: 28428158
Drug: Mobile health
Normalized name: Healthy Mama
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mobile health intervention (smartphone app) for medication and symptom management
Study: 28428225
Drug: Empagliflozin treatment
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin treatment for 2 days
Study: 28428225
Drug: Empagliflozin treatment
Normalized name: Empagliflozin
DrugBank: Empagliflozin (DB09038)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Empagliflozin treatment for 14 days
Study: 28428882
Drug: Immunotherapy treated
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Immunotherapy treated mice
Study: 28428882
Drug: Patients undergoing
Normalized name: patent blue violet
DrugBank: Patent Blue (DB13967)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients undergoing systemic high dose IL-2
Study: 28428884
Drug: Imatinib 400
Normalized name: imatinib 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Imatinib 400 mg twice daily and ipilimumab 3 mg/kg every 3 weeks
Study: 28429083
Drug: Fully implantable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fully implantable treprostinil infusion pump
Study: 28432691
Drug: Tenapanor 15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tenapanor 15 mg twice daily over 4 days
Study: 28432691
Drug: Cefadroxil 500
Normalized name: cefadroxil 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil 500 mg for 1 day
Study: 28432691
Drug: Cefadroxil 500
Normalized name: cefadroxil 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cefadroxil 500 mg and Tenapanor 15 mg on day 5
Study: 28433924
Drug: 50-mg deuterium-labeled
Normalized name: strontium chloride, 89Sr-labeled
DrugBank: Strontium chloride Sr-89 (DB09498)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50-mg deuterium-labeled methyl d9-TMAO (d9-TMAO)
Study: 28434648
Drug: Nivolumab 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab 3 mg/kg every 2 weeks (dose-expansion phase)
Study: 28434648
Drug: Nivolumab (dose-escalation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nivolumab (dose-escalation phase)
Study: 28434702
Drug: Telmisartan, 10
Normalized name: Amlodipine Besylate-Telmisartan, 10 mg-40 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Telmisartan, 10 mg/kg/d in chow
Study: 28434702
Drug: GW9662, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: GW9662, 3 mg/kg/d through oral gavage
Study: 28434702
Drug: AT1a KO
Normalized name: niacin
DrugBank: Niacin (DB00627)
Approvals — FDA: no, EMA: no, PMDA: no
Description: AT1a KO mice (no treatment mentioned)
Study: 28434944
Drug: rVSV-ZEBOV (highest
Approvals — FDA: no, EMA: no, PMDA: no
Description: rVSV-ZEBOV (highest dose cohort)
Study: 28436937
Drug: BPS804 (5,
Approvals — FDA: no, EMA: no, PMDA: no
Description: BPS804 (5, 10, and 20 mg/kg) administered intravenously on days 1, 15, and 29
Study: 28437326
Drug: Intravenous fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fish oil-based lipid emulsion (FishLE) at a dosage of 1 g·kg·day until resolution of direct hyperbilirubinemia or return of enteral nutrition.
Study: 28437326
Drug: Intravenous fish
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous fish oil-based lipid emulsion (FishLE)
Study: 28437488
Drug: Oseltamivir 75
Normalized name: oseltamivir 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oseltamivir 75 mg single oral dose in c.662AG subjects
Study: 28438728
Drug: Text messaging
Approvals — FDA: no, EMA: no, PMDA: no
Description: Text messaging intervention (twice daily for 6 months) tailored to participant's stage of behavior change
Study: 28441027
Drug: β-Blocker Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: β-Blocker Therapy
Study: 28441111
Drug: Pembrolizumab 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 200 mg once every 3 weeks
Study: 28442212
Drug: Underwater ultrasound
Normalized name: ULTRASOUND
Approvals — FDA: no, EMA: no, PMDA: no
Description: Underwater ultrasound therapy
Study: 28442293
Drug: Appropriate therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Appropriate therapy (active drug against the blood isolate started in the first 5 days after infection)
Study: 28442293
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy (more than one active drug) among those receiving appropriate therapy
Study: 28442293
Drug: Monotherapy (only
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy (only one active drug) among those receiving appropriate therapy
Study: 28442293
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy in high-mortality-score stratum
Study: 28442293
Drug: Monotherapy in
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy in high-mortality-score stratum
Study: 28442293
Drug: Combination therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination therapy in low-mortality-score stratum
Study: 28442293
Drug: Monotherapy in
Normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Monotherapy in low-mortality-score stratum
Study: 28444114
Drug: Everolimus (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Everolimus (10 mg/day, orally) plus octreotide LAR (30 mg, intramuscularly, every 28 days)
Study: 28444114
Drug: Placebo plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo plus octreotide LAR (30 mg, intramuscularly, every 28 days)
Study: 28444156
Drug: Fractional intradermal
Normalized name: plasma protein fraction Injection [Plasmanate]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fractional intradermal doses of the inactivated poliovirus vaccine (ID fIPV)
Study: 28446181
Drug: NMES applied
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: NMES applied to agonist muscles
Study: 28446244
Drug: Further antiepileptic
Normalized name: ANTIEPILEPTICS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Further antiepileptic drugs (AED)
Study: 28446495
Drug: High-volume energy
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-volume energy drink (946 mL, 320 mg caffeine)
Study: 28446495
Drug: Caffeinated control
Normalized name: Caffeine
DrugBank: Caffeine (DB00201)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Caffeinated control drink (320 mg caffeine)
Study: 28448562
Drug: All treatments
Normalized name: All Clear
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: All treatments (ETN, ADL, IFX)
Study: 28448594
Drug: HIVconsv vaccines
Normalized name: Pertussis vaccine
DrugBank: Pertussis vaccine (DB15274)
Approvals — FDA: no, EMA: no, PMDA: no
Description: HIVconsv vaccines
Study: 28448662
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with FLOT (fluorouracil, leucovorin, oxaliplatin, and docetaxel) followed by surgical resection in arm B (n=60)
Study: 28448662
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with FLOT in arm C (n=127)
Study: 28448662
Drug: Neoadjuvant chemotherapy
Normalized name: menthol
DrugBank: Menthol (DB14123)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Neoadjuvant chemotherapy with FLOT followed by surgery in arm B (n=36 who proceeded to surgery)
Study: 28449090
Drug: Acute alcohol
Normalized name: Alcohol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acute alcohol consumption (mean BAC 0.85 g/kg)
Study: 28449352
Drug: Ziconotide as
Normalized name: Ziconotide
DrugBank: Ziconotide (DB06283)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Ziconotide as the first agent in pump (FIP+)
Study: 28449352
Drug: Not first
Approvals — FDA: no, EMA: no, PMDA: no
Description: Not first intrathecal agent in pump (FIP-)
Study: 28449674
Drug: Exclusive chemotherapy
Normalized name: monofluorophosphate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exclusive chemotherapy
Study: 28450351
Drug: Adenosine (25
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adenosine (25 μg/kg; 1.5 mg if ≥60 kg)
Study: 28450894
Drug: Peginterferon beta-1a
Normalized name: Peginterferon Beta-1A
DrugBank: Peginterferon beta-1a (DB09122)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Peginterferon beta-1a 125 mcg every 2 weeks
Study: 28453692
Drug: Pembrolizumab 10
Normalized name: pembrolizumab 100 MG in 4 ML Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab 10 mg/kg intravenously every 2 weeks for up to 2 years or until progression or unacceptable toxicity
Study: 28453702
Drug: Pre-treatment in
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-treatment in vitro responses of immune biomarkers to TLR8 stimulation
Study: 28454793
Drug: Use of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use of adjunctive protective pelvic drapes
Study: 28457953
Drug: IFN-α treatment
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-α treatment (recombinant human IFN-α-2b injections administered subcutaneously 2 to 3 times per week for 6 months)
Study: 28457953
Drug: IFN-α treatment
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN-α treatment
Study: 28458770
Drug: Novel Herbal-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel Herbal-based Cream
Study: 28460039
Drug: Elevated high-sensitivity
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elevated high-sensitivity cardiac troponin T (hsTnT) levels (>14 ng/L)
Study: 28460039
Drug: Detectable hsTnT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Detectable hsTnT levels (5-14 ng/L)
Study: 28460039
Drug: Undetectable hsTnT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Undetectable hsTnT levels (<5 ng/L)
Study: 28461396
Drug: Pembrolizumab, 200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pembrolizumab, 200 mg IV every 2 weeks, pomalidomide 4 mg daily for 21 days, dexamethasone 40 mg weekly
Study: 28464732
Drug: Probenecid (250
Approvals — FDA: no, EMA: no, PMDA: no
Description: Probenecid (250 mg twice a day for 1 week, followed by 500 mg twice a day for 3 weeks)
Study: 28465300
Drug: Ticagrelor 90
Normalized name: ticagrelor 90 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ticagrelor 90 mg orally twice a day for 10 days
Study: 28465300
Drug: Clopidogrel 75
Normalized name: clopidogrel 75 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clopidogrel 75 mg orally once a day for 10 days
Study: 28465370
Drug: Ramucirumab 6
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ramucirumab 6 mg/kg every 2 weeks
Study: 28465370
Drug: Ramucirumab 10
Normalized name: ramucirumab 10 MG/ML
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ramucirumab 10 mg/kg every 3 weeks
Study: 29508095
Drug: Ramucirumab 8
Normalized name: Ramucirumab
DrugBank: Ramucirumab (DB05578)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Ramucirumab 8 mg/kg every 2 weeks
Study: 28465824
Drug: Manual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Manual therapy according to the School of Manual Therapy Utrecht (MTU)
Study: 28466686
Drug: Pre-operative concomitant
Normalized name: lidocaine
DrugBank: Lidocaine (DB00281)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Pre-operative concomitant hyperfractionated radiotherapy (HART) with co-administration of 5-fluorouracil (5FU), total dose 42 Gy in 28 fractions of 1.5 Gy, two times daily.
Study: 28468797
Drug: selinexor, 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: selinexor, 3 to 80 mg/m²
Study: 28468895
Drug: Vitamin B-6
Normalized name: Vitamin B-6 100mg Tablet
DrugBank: Pyridoxine (DB00165)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vitamin B-6 supplementation, dosage and duration not available
Study: 28468947
Drug: Intratumoral Injection
Normalized name: bimatoprost
DrugBank: Bimatoprost (DB00905)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Intratumoral Injection
Study: 28469486
Drug: Sodium Bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Bicarbonate with single dose of Calcium Gluconate (SBCG1)
Study: 28469486
Drug: Sodium Bicarbonate
Normalized name: Sodium Bicarbonate
DrugBank: Sodium bicarbonate (DB01390)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sodium Bicarbonate with double dose of Calcium Gluconate (SBCG2)
Study: 28470815
Drug: On-treatment virologic
Normalized name: benzoyl peroxide
DrugBank: Benzoyl peroxide (DB09096)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: On-treatment virologic failure
Study: 28471286
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICSs) adherence measured by a 4-item self-report questionnaire
Study: 28471286
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICSs) adherence measured by a single question (SQ)
Study: 28471286
Drug: Inhaled corticosteroids
Normalized name: CORTICOSTEROIDS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled corticosteroids (ICSs) adherence measured by medication possession ratio (MPR)
Study: 28472366
Drug: Enzalutamide or
Normalized name: enzalutamide Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enzalutamide or abiraterone in chemotherapy-naïve patients
Study: 28472487
Drug: 11-oxygenated steroids
Approvals — FDA: no, EMA: no, PMDA: no
Description: 11-oxygenated steroids (11OHA4, 11OHT, 11ketoT, 11ketoA4)
Study: 28472509
Drug: Temozolomide (TMZ)
Normalized name: Temozolomide
DrugBank: Temozolomide (DB00853)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Temozolomide (TMZ) 200 mg/m2 × 5/28 day for 6 cycles followed by myeloablative high-dose chemotherapy (HDC) with autologous stem-cell transplant (ASCT).
Study: 28472509
Drug: HDC (thiotepa
Approvals — FDA: no, EMA: no, PMDA: no
Description: HDC (thiotepa 250 mg/m2/day × 3 days, then busulfan 3.2 mg/kg/day × 3 days) followed by ASCT.
Study: 28472928
Drug: Pre-adherence preparation
Normalized name: cranberry preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pre-adherence preparation
Study: 28473851
Drug: Levothyroxine Replacement
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levothyroxine Replacement Therapy
Study: 28475354
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of glucose with insulin
Study: 28475354
Drug: Parenteral nutrition
Normalized name: parenteral nutrition solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: Parenteral nutrition containing amino acids
Study: 28475354
Drug: Infusion of
Normalized name: OIL OF CAMPHOR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infusion of amino acids in critically ill mice
Study: 28476136
Drug: Supervised group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supervised group exercise twice weekly for 12 weeks
Study: 28476148
Drug: Enhanced treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced treatment as usual (control group) with a leaflet about depression.
Study: 28476440
Drug: Subcutaneous rituximab
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Subcutaneous rituximab (375 mg/m2)
Study: 28476913
Drug: Immediate implant
Normalized name: IR-3535
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate implant insertion
Study: 28476913
Drug: Delayed implant
Normalized name: Drug Implant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Delayed implant insertion